Association of Obesity Based on Different Metabolic Status with Risk of Gout Occurrence in Patients: A National Study

Yanyan Wang; Xiude Fan; Xu Hou; Luna Liu; Shizhan Ma; Junming Han; Zhixiang Wang

doi:10.2174/1871530323666230911140635

Association of Obesity Based on Different Metabolic Status with Risk of Gout Occurrence in Patients: A National Study

Endocr Metab Immune Disord Drug Targets. 2023 Sep 11. doi: 10.2174/1871530323666230911140635. Online ahead of print.

Authors

Yanyan Wang^{1

2

3

4

5}, Xiude Fan^{6

2

3

4}, Xu Hou^{6

2

3

4}, Luna Liu^{1

2

3

4}, Shizhan Ma^{6

2

3

4}, Junming Han^{6

2

3

4}, Zhixiang Wang^{6

2

3

4}

Affiliations

¹ Department of Endocrinology, Shandong Provincial Hospital, Shandong University, Jinan, China.
² Shandong Clinical Research Center of Diabetes and Metabolic Diseases, Jinan, China.
³ Shandong Institute of Endocrine and Metabolic Diseases, Jinan, China.
⁴ Shandong Engineering Laboratory of Prevention and Control for Endocrine and Metabolic Diseases, Jinan, China.
⁵ Feicheng Hospital Affiliated to Shandong First Medical University, Tai'an, Shandong, 271600, China.
⁶ Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.

PMID: 37702179
DOI: 10.2174/1871530323666230911140635

Abstract

Background: Obesity often co-exists with metabolic abnormalities, but the results of studies on the relationship between obesity, metabolic abnormalities and the risk of gout are inconsistent.

Objective: We aimed to study whether there was a mutual regulation between obesity, metabolic abnormalities and the risk of gout.

Method: We conducted a cross-sectional study to expound the association between obesity based on different metabolic statuses and the risk of gout. Patients were derived from Nationwide Readmission Database (2018 sample).

Results: A total of 9,668,330 records were recruited for analysis from January to December. The risk of gout in the obesity group, metabolic abnormalities group and obesity combined with metabolic abnormalities group was 1.67 times (OR=1.67, 95%CI 1.64-1.70), 3.12 times (OR=3.12, 95%CI 3.09-3.15) and 4.27 times (OR=4.27, 95%CI 4.22-4.32) higher than that in the normal control group. For different metabolic components, OR value was highest in hypertension group (OR=2.65, 95%CI 2.60-2.70 and OR=4.85, 95%CI 4.73-4.97), followed by dyslipidemia group (OR=2.23, 95%CI 2.16-2.30 and OR=3.74, 95%CI 3.55-3.95) and in hyperglycemia group (OR=1.73, 95%CI 1.66-1.80 and OR=2.94, 95%CI 2.78-3.11). Fewer components of metabolic syndrome were associated with a lower risk of gout in both nonobese and obese patients.

Conclusion: When metabolic abnormalities were present, obesity induced a higher risk of gout. Different components of metabolic abnormalities had different effects on the risk of gout occurrence, and the number of metabolic abnormalities was closely related to the risk of gout occurrence. Follow-up and intervention methods targeting obesity and metabolic abnormalities should be considered for patients with gout.

Keywords: abnormalities; gout; hyperglycemia; hyperlipidemia; hypertension; metabolism; obesity.